ARTICLE | Clinical News
Necuparanib: Development discontinued
September 12, 2016 7:00 AM UTC
Momenta discontinued its necuparanib program after confirming the results of an independent DSMB’s interim futility analysis and reviewing the unblinded safety and efficacy data from a double-blind, p...